IOVANCE BIOTHERAPEUTICS, INC. IOVA Cash Flow

Iovance biotherapeutics, inc. (IOVA)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows from Operating Activities
Net loss
-69,600	-63,600	-49,500	-47,550	-36,950	-32,575	-33,830	-30,660	-26,515	-25,854	-22,149	-23,377	-20,684	-15,688	-18,759	-11,563	-6,884	-8,360	-7,635	-6,367	-5,298	-4,867	-2,798	-2,110	-2,259	-11,497	-9,409	-3,429	-1,046	3,466	-673	-327	-5,772	-8,351	-5,818	-10,959	-564
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
9,412	5,407	6,598	6,426	5,846	5,185	5,516	5,222	4,104	2,760	2,619	3,293	3,296	3,123	8,645	5,357	1,779	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash lease expense
1,870	1,989	1,934	1,607	1,424	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premiums on investments
-50	-386	-605	-1,198	-1,232	-944	-387	-1	0	0	-18	9	28	-5	-69	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Depreciation and amortization
252	294	315	289	271	252	251	225	228	242	246	243	221	290	148	271	269	308	266	240	185	65	5	1	16	2	1	1	1	1	1	1	1	-53	19	18	18
Gain on settlement of dispute
-	0	0	0	336	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of assets
-	-	-	-	-	0	0	0	-9	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of intangible asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	160	0	0	0
Fair value of vested stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,284	1,017	-	555	438	901	389	136	133	87	170	710	469	1,177	1,261	148	343	40
Fair value of derivative liability recorded upon issuance of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2,563	0	0
Amortization of discount on convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-497	0	0	-	-	-	-
Private placement costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	515	0	0	0	920	0	0
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	7,659	1,595	-3,168	2,548	-4,837	3,546	-398	93
Common stock issued to officer for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-90	8,100	0
Common stock issued for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	638	450	-	-	-	-	274	0	0	0	750	0	0	50	-1,040	1,473	65	0
Common stock issued to induce conversion of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122	0	-	-	-	-	-	-	-	-
Common stock issued to induce exchange transaction
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	122	2,173	0	-	-	-	-	-	-	-	-
Derivative liability recorded upon issuance of convertible notes and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-182	182	920	4,615	0	0
Derivative liability recorded as offering cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	515	0	182	0	0	0	642	0
Common stock issued to directors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-217	217
Fair value of common stock and warrants accounted for as financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	-
Vesting of restricted shares issued for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	384	423	17	-	-	-	0	0	0	0	0	-	-	-	-
Fair value of common stock transferred to officer and director
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	1,040	0	702	0
Write off of advances to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	50	0	0	0
Changes in assets and liabilities:
Prepaid expenses, other assets, and long-term assets
1,316	4,063	-1,300	2,107	-1,592	1,421	2,248	-1,972	368	-445	1,578	1,021	2,354	1,768	492	589	-84	48	-149	250	62	10	-23	-44	-49	162	-0	2	-0	2	-19	14	-20	-46	26	-7	6
Operating lease liabilities (Right-of-use assets)
-2,461	-1,834	-1,663	-1,709	-942	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-7,768	6,081	-3,326	5,368	4,583	-3,275	1,096	-1,553	5,239	-1,779	-839	1,521	1,466	480	-497	-329	96	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
4,364	2,242	2,752	5,080	-3,346	1,229	1,674	872	-546	3,222	273	1,836	-776	1,409	-1,185	3,105	104	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-250	866	-	-	-	-
Accrued interest and penalty
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	341	-	-	-	-	-	-	-	-
Accounts payable, accrued expenses and interest and penalty
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	107	58	42
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	989	-45	249	-	101	-120	-993	-768	-305	659	316	-182	1,357	327	372	-	0	0	0
Accrued compensation payable in shares of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-65,300	-53,800	-42,200	-33,810	-29,090	-31,549	-27,928	-23,923	-17,849	-20,964	-21,446	-17,496	-18,803	-12,159	-12,209	-3,748	-4,552	-6,580	-3,842	-4,500	-3,459	-3,315	-1,728	-1,322	-2,267	-2,251	-427	-681	-300	0	-280	-1,200	-760	-2,709	-1,649	-1,265	-564
Cash Flows from Investing Activities
Maturities of short-term investments
113,665	94,021	157,478	172,060	91,042	-	-	-	0	0	14,750	25,355	19,600	26,505	26,278	28,726	39,155	54,700	11,900	4,000	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bank overdraft
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	-	-	-	-
Purchase of money market funds
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of short-term investments
12,923	63,781	152,749	111,944	89,185	247,087	148,910	30,084	0	-	-	-	-	0	41,909	39,067	29,273	45,429	-1,045	96,281	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
637	3,426	1,234	1,433	824	295	463	418	22	-58	263	25	798	740	725	54	2	151	73	137	782	1,425	161	2	3	-	-	-	-	0	0	0	0	10	3	16	0
Advances to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	50	-50	0	50
Net cash provided by investing activities
100,105	26,814	3,495	58,683	1,033	-206,382	-149,373	-30,502	-22	58	14,487	25,330	18,802	25,765	-16,356	-10,395	9,880	9,120	20,349	-99,895	-782	-	-	-	-	-0	-12	0	0	0	0	0	0	-60	46	-16	-50
Tax payments related to shares withheld for vested restricted stock awards
118	119	98	24	71	42	59	60	62	49	42	1,157	4	288	5	349	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the issuance of common stock upon exercise of warrants
-	-	-	-	-	1,070	10,543	2,315	1,826	274	138	94	156	356	258	621	0	87	1,643	5,671	2,304	220	638	1,820	542	0	0	0	0	-	-	-	-	-	-	-	-
Proceeds from the issuance of common stock upon exercise of options
3,951	2,207	762	3,405	69	1,593	1,538	1,198	5,630	3,062	1,908	415	231	148	241	237	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the issuance of secured promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from the issuance of common stock, net
-	-	-	-	-	-	0	-93	162,186	-	54,050	0	0	-	-	-	-	-	-	-	68,308	-	-	-	-	5,885	0	1,240	0	0	0	0	250	0	0	828	45
Proceeds from the issuance of preferred stock and common stock, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from the issuance of convertible notes, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	0	11	300	0	0	0	0	2,320	2,295	0	0
Due to director
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Net cash provided by / (used in) financing activities
3,833	2,088	664	3,381	-2	239,345	12,022	3,360	169,580	2,899	56,054	-648	383	216	494	96,194	0	275	1,709	5,671	70,612	32,460	638	1,820	542	21,794	0	1,251	300	0	265	1,216	250	2,370	2,245	828	45
Net increase / (decrease) in cash, cash equivalents and restricted cash
38,646	-24,920	-38,023	28,269	-28,059	1,414	-165,279	-51,065	151,709	-18,007	49,095	7,186	382	13,822	-28,071	82,051	5,328	2,815	18,216	-98,724	66,371	27,720	-1,251	496	-1,728	19,542	-439	569	0	0	-15	15	-510	-400	642	-454	-569
Supplemental disclosure of cash flow information:
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash investing and financing activities:
Net unrealized gain on short-term investments
692	-	-	-	180	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net unrealized gain (loss) on short-term investments
692	-19	-133	234	180	78	-117	-3	0	0	0	-2	-27	-134	85	10	20	0	26	22	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisitions of property and equipment included in accounts payable and accrued expenses
4,686	-435	465	-176	268	-	-	266	12	-	0	0	-155	155	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs under accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-93	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forgiveness of debt by director, treated as contribution of capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Common stock issued upon conversion of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Fair value of common stock issued with notes payable recorded as a note discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Settlement of accounts payable through issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Common stock issued upon conversion of accrued interest and penalty
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,792	0	9,267	0	-	-	-	-	-	-	-	-